Ann D Kwong is an internationally recognized industry leader in antiviral drug discovery and development and a co-founder of HCV DRAG (HCV Drug Development Advisory Group), a consortium of industry, clinical trial, community, and regulatory leaders working to optimize HCV drug development. Ann is the co-founder, President and CEO of Trek Therapeutics which is committed to developing affordable and accessible drugs to treat infectious diseases. Trek is conducting Ph2 clinical trials to develop a potentially best-in-class and affordable regimen to cure HCV. Prior to Trek, Ann founded the infectious disease group at Vertex Pharmaceuticals and played a leading role in the discovery, development, and commercialization of VX-787, a PB2 flu inhibitor currently in Ph2, and telaprevir (INCIVEK), a HCV inhibitor with >$2B in sales (Kwong, et al. (2011). Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotech 29:1-11. Ann D Kwong is an internationally recognized industry leader in antiviral drug discovery and development and a co-founder of HCV DRAG (HCV Drug Development Advisory Group), a consortium of industry, clinical trial, community, and regulatory leaders working to optimize HCV drug development. Ann is the co-founder, President and CEO of Trek Therapeutics which is committed to developing affordable and accessible drugs to treat infectious diseases. Trek is conducting Ph2 clinical trials to develop a potentially best-in-class and affordable regimen to cure HCV. Prior to Trek, Ann founded the infectious disease group at Vertex Pharmaceuticals and played a leading role in the discovery, development, and commercialization of VX-787, a PB2 flu inhibitor currently in Ph2, and telaprevir (INCIVEK), a HCV inhibitor with >$2B in sales (Kwong, et al. (2011). Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat Biotech 29:1-11.

Gastroenterology